Financing rounds: OriCiro Genomics, Hochuen Medical Technology, Juventas Cell Therapy, PEP-Therapy, Anocca, Hemab

European biotech companies took on funds this week as they take the next steps in their development journey. Anocca and PEP-Therapy are moving onto Phase I trials and Hemab is building up its management team with an eye to the US market.   Denmark: Hemab, a biotech company developing next generation therapeutics for serious underserved…

You must be a HMI Subscriber to view this content.

Subscribe Now »